We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Characterizing PAI-1 Modulation on Monocyte Adhesion

This study has been terminated.
(Investigator left institution)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00512031
First Posted: August 7, 2007
Last Update Posted: July 18, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Vanderbilt University
  Purpose
To determine how altering the expression of a gene known as PAI-1 may affect the adhesive capacity of cells that play a critical role in the developement of human atherosclerosis.

Condition
Atherosclerosis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Characterizing the Effects of PAI-1 Modulation on Human Monocyte Function - The Effect of PAI-1 Post-transcriptional Regulation on Human Monocyte Adhesion

Resource links provided by NLM:


Further study details as provided by Vanderbilt University:

Estimated Enrollment: 50
Study Start Date: January 2007
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Detailed Description:
The principal aim of this study is to determine if molecular regulation of the human gene PAI-1 alters the migratory properties of human myeloid and endothelial cells sufficiently enough to regulate entry and exit from the vascular space. Human monocyte become the key cellular orchestrators of human atherosclerotic plaque. We believe that a "loss" of PAI-1 activity may promote a pro-atherogenic effect in human vasculature thereby defining a novel atheroprotective effect for PAI-1 when expressed at normal levels in humans. By using RNA interference to achieve PAI-1 gene, we hope to elucidate the mechanistic basis of how PAI-1 regulation may affect human migration within the vasculature.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Healthy volunteers
Criteria

Inclusion Criteria:

  • Ages 18-50
  • No current or past medical problems

Exclusion Criteria:

  • Patients taking prescription drugs (hormonal birth control or herbal supplements may be taken)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00512031


Locations
United States, Tennessee
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232-6300
Sponsors and Collaborators
Vanderbilt University
Investigators
Principal Investigator: Mohan Sathyamoorthy, MD Vanderbilt University
  More Information

Responsible Party: Mohan Sathyamoorthy, Vanderbilt University
ClinicalTrials.gov Identifier: NCT00512031     History of Changes
Other Study ID Numbers: 070079
First Submitted: August 3, 2007
First Posted: August 7, 2007
Last Update Posted: July 18, 2011
Last Verified: July 2011

Keywords provided by Vanderbilt University:
atherosclerosis
metabolic pathways
monocyte adhesion,

Additional relevant MeSH terms:
Atherosclerosis
Tissue Adhesions
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Cicatrix
Fibrosis
Pathologic Processes